|
|
|
|
|
|
RIG-I Activating DNA Vaccine Vectors
|
NTC PRODUCTS AND SERVICES
|
|
|
|
|
|
|
XXVersions
|
Kanamycin resistance selectable markert (KanR gene):
NTC7485-eRNA41H-EGFP – native, Kanamycin selection, EGFP control gene (can be used to clone a gene of
NTC7482-eRNA1H – secreted (TPA tag), Kanamycin selection, can be used to clone a gene of interest
Antibiotic-Free (SacB gene, sucrose resistance):
NTC8485-eRNA41H-EGFP – equivalent to NTC7485-eRNA41H-EGFP, above, except for antibiotic-free selection on sucrose
NTC8482-eRNA41H – secreted (TPA tag), equivalent to NTC7482-eRNA41H, above, except for antibiotic-free selection on sucrose
|
| XXDescription |
Co-stimulation, in addition to antigen presentation, is an essential property of vaccines that was often ignored in early stage DNA vaccine backbones. Antigen expression in the absence of co-stimulation can result in anergy and tolerance. NTC’s RNA elements (eRNAtm) are designed to mimic Pathogen Associated Molecular Patterns (PAMPS), such as double stranded RNA and RNA hairpins, which are agonists of the innate response genes, retinoic acid inducible gene 1 (RIG-1) and melanoma differentiation antigen 5 (mda5). Synergistic activation by RNAe™ (Fig. 1, below) resulted in dramatic enhancement of Type I interferon production, as well as improved antibody responses and avidity.
RNAe™ vaccine vectors are available either as traditional Kanamycin resistance vectors, or as antibiotic-free versions of our popular NTC7482 and NTC7485 vaccine/expression vectors. The RNAetm, 41H, is a 760bp region inserted into the vector backbone (Fig. 2, below). The 41H vector series was rationally designed as a safe, minimalized selection set, for the expression of antigens in vivo for genetic immunization (DNA vaccines).
|
| XXFeatures: |
• Enhanced antigen expression in mammalian cells
• Compliance with FDA guidance
• Improved antibody response
• Improved antibody avidity
• Kanamycin or RNA-OUT (antibiotic free) selectable markers
• Improved DNA backbone for maximum plasmid production (>2.5g/L)
• Enhanced co-stimulatory RNAetm activates RIG-1 pathway, Type I interferon production
• Optimized, chimeric promoter-intron (SV40-CMV-HTLV-1 R-U5-synthetic intron)
• Superior E. coli plasmid production yields (>2.5g/L)
• Optional TPA secretion tag
|
| XXVector Specifications: |
Fig. 1. Left: RIG-1 activation of IFNβ promoter-luciferase reporter (ratio of luciferase to EGFP internal transfection control). Synergistic RIG-1 activation by plasmid-borne eRNA VA RNA1 and eRNA 11a combination (eRNA41H). Right: Antibody avidity after prime (T=21 days) and boost (T=49 days) IM immunizations).
Fig. 2. NTC8482-eRNA41H. Compliance with regulatory guidance for DNA vaccine vectors
|
|
Contact NTC, Toll free: 1-(888) WIZ-BANG
|
|
|
